<DOC>
	<DOCNO>NCT01656590</DOCNO>
	<brief_summary>The research protocol submit approval institutional review board Columbia University Medical Center . An attempt make recruit least 6 juvenile patient age 8 17 , preferably still ambulatory . Subjects meet eligibility criterion undergo full history physical examination , include detail age onset symptom , distribution severity muscle weakness , muscle function , pulmonary function , nutritional status . Subjects undergo electrocardiogram ( ECG ) , spirometry , muscule strength evaluation , exercise capacity , functional muscle test , laboratory test , muscle biopsy . Quality life assess via SF 36 questionnaire . Functional ability level handicap assess Rotterdam handicap scale . Written inform consent obtain subject . All patient , receive enzyme replacement therapy ( ERT ) least 2 year , evaluate prior institution high protein nutrition exercise therapy plus nocturnal enteral feeding ( HPET + NEF ) ( baseline ) , 3 month , 6 month 12 month treatment . The following parameter evaluated- - Skeletal Muscle Function - Biochemical parameter collect blood sample Muscle Biopsy obtain baseline 12 month . Biopsy specimens , obtain thigh muscle baseline repeat biopsy correspond area leg 12 month , analyze follow : . - Histology electron microscopy - Autophagic lysosomal function evaluation - Body composition Body mass index ( BMI ) , body composition , lean body mass , fat mass measure visit bioelectric impedance analysis use BI-101Q RJL Systems , software 3.1b</brief_summary>
	<brief_title>High Protein Exercise Therapy Plus Nocturnal Enteral Feeding Juvenile-onset Pompe Disease</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<criteria>1 . Male female , 8 17 year age . 2 . Diagnosis Pompe disease ; either enzyme deficiency muscle biopsy specimen skin fibroblast culture , homozygous compound heterozygous GAA mutation . 3 . Muscle Function &lt; grade 7 Walton Scale . 4 . Women reproductive age ( &gt; 15 year ) agree use reliable method contraception study , sexually active 5 . Subject legal representative willing able provide write informed consent . 1 . Any intercurrent condition may preclude accurate interpretation study data 2 . Obstructive pulmonary disease 3 . Invasive ventilatory support 4 . Noninvasive ventilatory support awake upright position 5 . History QTc prolongation &gt; 450 msec male &gt; 470 msec female 6 . Life expectancy &lt; 1 year 7 . History allergy , sensitivity serious adverse reaction rhGAA drug 8 . Pregnancy 9 . Current recent drug alcohol abuse . 10 . Treatment another investigational drug within 60 day study start 11 . Use prohibit medication &lt; 3 month prior randomization 12 . Otherwise unsuitable study opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pompe disease</keyword>
	<keyword>Acid Maltase Deficiency</keyword>
</DOC>